BMS-986369

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

6 competitors in T - Cell Lymphoma

#DrugCompanyPhaseTrials

1

Jakafi

Incyte

Phase 2

22

Rituxan

Roche

Phase 2

13

Idhifa

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

14

Fenretinide

EEastern Cooperative Oncology Group

Phase 1

15

CD4CAR

HHuda Salman

Phase 1

16

BMS-986369

Bristol-Myers Squibb

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Metabolism1 trial

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT05567510·8 enrolled

Single Ascending Dose1 trial

A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT05350800·68 enrolled

Hepatic Impairment1 trial

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Completed·Bristol-Myers Squibb·Phase 1·NCT06535399·29 enrolled

T - Cell Lymphoma1 trial

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Active, not recruiting·Bristol-Myers Squibb·Preclinical·NCT06035497·83 enrolled

Details

Drug Info

Related News